Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

NCT: NCT04089059 · ACTIVE_NOT_RECRUITING

NCT IDNCT04089059
StatusACTIVE_NOT_RECRUITING
Start Date2020-01-10
Completion2028-04
SponsorEndotronix, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

Frequently Asked Questions

What is PROACTIVE-HF IDE Trial Heart Failure NYHA Class III?

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III is a clinical trial registered under NCT04089059. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04089059?

The current status of NCT04089059 (PROACTIVE-HF IDE Trial Heart Failure NYHA Class III) is: ACTIVE_NOT_RECRUITING.

When did PROACTIVE-HF IDE Trial Heart Failure NYHA Class III start?

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III started on 2020-01-10.

Related Devices

PMA P230040System, hemodynamic, implantableEndotronix, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑